Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: RECIST 1.1 criteria have been challenged for the evaluation of treatment response in NET.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: de Mestier L, Dromain C, Lamarca A, La Salvia A, Op de Beeck B,
Keywords: imaging criteria, response evaluation, CT scan,
Introduction: Increase of Ki-67 index in NEN over time in relation to progression and a potential influence on prognosis is scarcely studied.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Holmager P
Authors: Holmager P, Langer S, Federspiel B, Willemoe G, Garbyal R,
Keywords: Ki-67 index, Prognosis, Mortality,
#2820 Efficacy of Peptide Receptor Radionuclide Therapy for Esthesioneuroblastoma
Introduction: Esthesioneuroblastoma (ENB) is a rare malignancy with limited therapeutic options when unresectable or metastatic. The overexpression of cell-surface somatostatin receptors in ENB is a potential molecular target making it amenable to peptide receptor radionuclide therapy (PRRT). High-level evidence supporting PRRT has been published for unresectable gastroenteropancreatic neuroendocrine tumours; however, data is limited for PRRT efficacy for ENB.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Kamel Hasan O
Authors: Kamel Hasan O, Ravi Kumar A, Kong G, Grozinsky-Glasberg S, Hicks R,
Keywords: esthesioneuroblastoma, peptide receptor radionuclide therapy, lutetium-177 dotatate,
Introduction: Response evaluation and prediction of outcome of a neuroendocrine tumor (NET) remains difficult.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Staal F, Taghavi M, van Treijen M, Tesselaar M, Beets-Tan R,
Keywords: Radiomics, CT, Liver metastases, Response, Outcome prediction,
Introduction: Response Evaluation Criteria In Solid Tumors (RECIST) are not presumably the most optimal option for predicting the benefit of antiangiogenic drugs in neuroendocrine tumors (NETs), given that tumor shrinkage is not frequent, and qualitative changes in tumor tissues are to be expected.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Carmona-Bayonas A, Fernandez del Valle A, Solis M, Matos I, Garcia-Carbonero R,
Keywords: CHOI criteria, pancreatic neuroendocrine tumor, RECIST, response, survival,